Christine Dierks, MD, describes the prognosis of the anaplastic thyroid carcinoma and differentiated thyroid cancer populations.
Christine Dierks, MD, senior physician at the University Hospital Freiburg in Germany, describes the prognosis of the anaplastic thyroid carcinoma and differentiated thyroid cancer populations.
Dierks says that the prognosis is very poor for both patient populations but especially for those with anaplastic thyroid carcinoma. Poor outcomes are seen with patients who have anaplastic thyroid carcinoma even if they have combined therapy, which can include surgery and radiotherapy, followed by chemotherapy. In these patients, the life expectancy is about 4 to 5 months after therapy, according to Dierks.
In terms of survival, there is an exception for patients who had BRAF-positive disease because imatinib (Gleevec) is available for these patients. Dierks notes that for the other 80% of patients, the prognosis remains poor due to a lack of agents.
Anticipating Novel Options for the RAI-Refractory DTC Armamentarium
May 15th 2023In season 4, episode 6 of Targeted Talks, Warren Swegal, MD, takes a multidisciplinary look at the RAI-refractory differentiated thyroid cancer treatment landscape, including the research behind 2 promising systemic therapy options.
Listen
Real-World Study Confirms Lenvatinib's Benefit in RAI-Refractory DTC
July 3rd 2024In an interview with Targeted Oncology, Francis P. Worden, MD, delved into the rationale behind the study and the implications of this research for patients with radioidine-refractory differentiated thyroid cancer.
Read More
Petosemtamab and Pembrolizumab: A Promising Pair in HNSCC Treatment
July 2nd 2024In an interview, Cesar Augusto Perez, MD, delved into the findings from a phase 2 study evaluating petosemtamab plus pembrolizumab in patients with recurrent/metastatic head and neck squamous cell carcinoma.
Read More
Wirth Explores Challenges of Therapy Selection for RAI-Refractory Differentiated Thyroid Cancer
June 28th 2024During a Case-Based Roundtable® event, Lori J. Wirth, MD, discussed with participants how they approach use of lenvatinib and other therapy for patients with radioactive iodine–refractory differentiated thyroid cancer.
Read More